Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art. (Q33819835)

29 July 2017

title

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art. (English)

1 reference

29 July 2017

main subject

coronary artery disease

1 reference

Tan HC

1

1 reference

29 July 2017

Harrington RA

series ordinal

2

1 reference

29 July 2017

Tcheng JE

series ordinal

3

1 reference

29 July 2017

publication date

1 January 1997

1 reference

29 July 2017

number of pages

9

1 reference

Journal of Thrombosis and Thrombolysis

inferred from page(s)

published in

1 reference

29 July 2017

volume

4

1 reference

29 July 2017

issue

3/4

1 reference

29 July 2017

page(s)

431-439

1 reference

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

29 July 2017

cites work

1 reference

12 December 2020

Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile

1 reference

12 December 2020

Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia

1 reference

12 December 2020

Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin

1 reference

12 December 2020

Glanzmann's thrombasthenia: the spectrum of clinical disease

1 reference

12 December 2020

Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry

1 reference

12 December 2020

Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri

1 reference

12 December 2020

The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators

1 reference

12 December 2020

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

12 December 2020

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

12 December 2020

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

12 December 2020

Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Systemic lysis protects against the effects of platelet activation during coronary thrombolysis

1 reference

12 December 2020

Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model

1 reference

12 December 2020

The platelet membrane glycoprotein IIb-IIIa complex.

1 reference

12 December 2020

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

1 reference

12 December 2020

Cyclic RGD peptide analogues as antiplatelet antithrombotics

1 reference

12 December 2020

1 reference

12 December 2020

Care of the patient receiving ReoPro following angioplasty

1 reference

12 December 2020

Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial

1 reference

12 December 2020

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

1 reference

12 December 2020

Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model

1 reference

12 December 2020

EPILOG and CAPTURE trials halted because of positive interim results

1 reference

12 December 2020

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

12 December 2020

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

12 December 2020

Acute coronary events associated with percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Restenosis after arterial angioplasty: A hemorrheologic response to injury

1 reference

12 December 2020

Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors

1 reference

12 December 2020

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

1 reference

12 December 2020

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

12 December 2020

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1008809702729

1 reference

Dimensions Publication ID

29 July 2017

1045968521

0 references

1 reference